Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Gulbenkian Institute For Molecular Medicine has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner and 1 distinct art unit. Juliana Irene Candelaria is the busiest examiner, responsible for 1 pending office action. This represents the entirety of the institute's current pending prosecution, with no other matters active.
The focus on 1 distinct examiner and 1 distinct art unit for the 1 pending office action indicates a highly centralized prosecution effort. Juliana Irene Candelaria is the sole examiner currently assigned to the portfolio's pending work. With only 1 pending office action, the institute's current engagement with the patent office is very narrow. This concentration in the Biotechnology & Pharmaceuticals area ensures that all current prosecution activity is directed toward a single examiner and a single technical group.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CANDELARIA, JULIANA IRENE | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18857803 | MESENCEPHALIC ASTROCYTE-DERIVED NEUROTROPHIC FACTOR (MANF) FOR INCREASING MUSCLE REGENERATION | CANDELARIA, JULIANA IRENE | — |
| Art Unit | Apps |
|---|---|
| 1634 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18857803 | MESENCEPHALIC ASTROCYTE-DERIVED NEUROTROPHIC FACTOR (MANF) FOR INCREASING MUSCLE REGENERATION | CANDELARIA, JULIANA IRENE | 1634 | §102§112 | Non-Final OA | — | Pending | Oct 17, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGulbenkian Institute For Molecular Medicine has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Juliana Irene Candelaria has the most, with 1 of Gulbenkian Institute For Molecular Medicine's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
